<p>Channel Wealth LLC 在第一季度將其在安進公司（NASDAQ:AMGN - 免費報告）的持股減少了 64.8%，根據其最近向證券交易委員會（SEC）的披露。這家機構投資者在該季度出售了 3,851 股後，持有 2,090 股該醫療研究公司的股票。根據其最近的 SEC 文件，Channel Wealth LLC 在安進的持股價值為 651,000 美元。</p>
<ul>
<li>三家生物科技巨頭受益於美國銷售和政策變化</li>
</ul>
<p>其他一些機構投資者和對沖基金也對其在該公司的持倉進行了調整。Capital World Investors 在第四季度將其在安進的股份增加了 1,292.0%。Capital World Investors 現在擁有 6,495,710 股該醫療研究公司的股票，價值 1,693,042,000 美元，此前在上個季度又購買了 6,029,058 股。挪威銀行在第四季度購買了安進的新股份，價值約為 1,541,991,000 美元。GAMMA Investing LLC 在第一季度將其在安進的股份增加了 43,573.5%。GAMMA Investing LLC 現在擁有 3,661,589 股該醫療研究公司的股票，價值 1,140,768,000 美元，此前在上個季度又購買了 3,653,205 股。Capital International Investors 在第四季度將其在安進的股份增加了 40.1%。Capital International Investors 現在擁有 12,212,065 股該醫療研究公司的股票，價值 3,182,843,000 美元，此前在上個季度又購買了 3,495,503 股。最後，查爾斯·施瓦布投資管理公司在第四季度將其在安進的股份增加了 25.4%。查爾斯·施瓦布投資管理公司現在擁有 13,205,604 股該醫療研究公司的股票，價值 3,441,909,000 美元，此前在上個季度又購買了 2,672,975 股。目前 76.50% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>安進股票表現</h2>
<p>NASDAQ:AMGN 週四開盤價為 287.01 美元。該公司的市值為 1543.3 億美元，市盈率為 38.01，市盈增長比率為 2.63，貝塔值為 0.51。該公司的 50 日移動平均價格為 282.39 美元，200 日移動平均價格為 285.31 美元。安進的債務與股本比率為 9.62，流動比率為 1.26，速動比率為 0.95。安進公司的 12 個月最低價為 253.30 美元，12 個月最高價為 346.85 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 12/2 - 12/6</li>
</ul>
<p>安進（NASDAQ:AMGN - 獲取免費報告）最近一次發佈財報是在 5 月 1 日，醫療研究公司報告該季度每股收益為 4.90 美元，超出市場共識預期的 4.18 美元，超出 0.72 美元。該季度的收入為 81.5 億美元，而分析師預期為 80.5 億美元。安進的股本回報率為 176.32%，淨利潤率為 12.24%。安進該季度的收入較去年同期增長了 9.4%。在去年同期，該公司每股收益為 3.96 美元。平均而言，賣方分析師預計安進公司在當前財年將發佈每股收益 20.62 美元。</p>
<h2>分析師評級變動</h2>
<p>幾位研究分析師最近對該公司進行了評估。Guggenheim 在 5 月 20 日的報告中開始覆蓋安進，給予 “中性” 評級和 288.00 美元的目標價。富國銀行在 2 月 5 日的報告中重申了對安進股票的 “持平” 評級。Erste Group Bank 在 5 月 8 日的報告中將安進的評級從 “強力買入” 下調至 “持有”。花旗集團在 2 月 5 日的報告中重申了對安進股票的 “中性” 評級。最後，美國銀行在 3 月 5 日的報告中將安進的目標價從 275.00 美元上調至 294.00 美元，並給予該公司 “表現不佳” 的評級。兩位股票研究分析師給予該股票 “賣出” 評級，十二位給予 “持有” 評級，九位給予 “買入” 評級，二位給予 “強力買入” 評級。根據 MarketBeat 的數據，安進目前的平均評級為 “持有”，共識目標價為 309.22 美元。</p>
<ul>
<li>安進股票因減肥藥數據下跌：過度反應還是合理？</li>
</ul>
<p><strong>查看我們對安進的最新分析</strong></p>
<h2>安進簡介</h2>
<p>（免費報告）</p>
<p>安進公司在全球範圍內發現、開發、生產和交付人類治療藥物。該公司的主要產品包括用於治療斑塊型銀屑病、類風濕性關節炎和銀屑病關節炎的恩利昔單抗；用於治療成人斑塊型銀屑病、銀屑病關節炎和與貝赫切特病相關的口腔潰瘍的 Otezla；用於治療絕經後女性骨質疏鬆症的 Prolia；用於預防骨骼相關事件的 XGEVA；可減少心肌梗死、中風和冠狀血管重建風險的 Repatha；用於治療免疫性血小板減少症患者的 Nplate；用於治療複發性或難治性多發性骨髓瘤患者的 KYPROLIS；用於治療紅細胞數量低於正常水平和貧血的 Aranesp；用於治療絕經後男性和女性骨質疏鬆症的 EVENITY；用於治療野生型 RAS 轉移性結直腸癌患者的 Vectibix；用於治療急性淋巴細胞白血病患者的 BLINCYTO；用於治療甲狀腺眼病的 TEPEZZA；以及用於治療慢性難治性痛風的 KRYSTEXXA。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票超過安進</li>
<li>加拿大便士股票：它們能讓你致富嗎？</li>
<li>Intuit 的人工智能熱潮：股票飆升，但投資者應該暫停嗎？</li>
<li>選舉股票：選舉如何影響股市</li>
<li>強分析師評級的頂級分紅股票</li>
<li>ETF 支付分紅嗎？你需要知道的</li>
<li>Robinhood 股票持續給投資者買入理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即時新聞提醒是由敍事科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在安進嗎？</h2>
<p>在考慮安進之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而安進並不在名單上。</p>
<p>雖然安進目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

安進

<p>Channel Wealth LLC 在第一季度減少了對安進（Amgen Inc.，NASDAQ:AMGN）64.8% 的持股，目前持有 2,090 股，價值 65.1 萬美元。其他機構投資者，包括 Capital World Investors 和 GAMMA Investing LLC，顯著增加了對安進的持倉。該股票開盤價為 287.01 美元，市值為 1543.3 億美元。安進報告第一季度每股收益為 4.90 美元，超出預期，營收為 81.5 億美元，同比增長 9.4%。分析師對該股票的評級不一，平均評級為 “持有”，共識目標價為 309.22 美元</p>

<p>Channel Wealth LLC cut its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 64.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,090 shares of the medical research company's stock after selling 3,851 shares during the quarter. Channel Wealth LLC's holdings in Amgen were worth $651,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Channel Wealth LLC 在第一季度將其在安進公司（NASDAQ:AMGN - 免費報告）的持股減少了 64.8%，根據其最近向證券交易委員會（SEC）的披露。這家機構投資者在該季度出售了 3,851 股後，持有 2,090 股該醫療研究公司的股票。根據其最近的 SEC 文件，Channel Wealth LLC 在安進的持股價值為 651,000 美元。</p>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>三家生物科技巨頭受益於美國銷售和政策變化</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also made changes to their positions in the business. Capital World Investors increased its stake in Amgen by 1,292.0% during the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock worth $1,693,042,000 after buying an additional 6,029,058 shares in the last quarter. Norges Bank purchased a new stake in Amgen during the 4th quarter worth approximately $1,541,991,000. GAMMA Investing LLC increased its stake in Amgen by 43,573.5% during the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock worth $1,140,768,000 after buying an additional 3,653,205 shares in the last quarter. Capital International Investors increased its stake in Amgen by 40.1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after buying an additional 3,495,503 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after purchasing an additional 2,672,975 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金也對其在該公司的持倉進行了調整。Capital World Investors 在第四季度將其在安進的股份增加了 1,292.0%。Capital World Investors 現在擁有 6,495,710 股該醫療研究公司的股票，價值 1,693,042,000 美元，此前在上個季度又購買了 6,029,058 股。挪威銀行在第四季度購買了安進的新股份，價值約為 1,541,991,000 美元。GAMMA Investing LLC 在第一季度將其在安進的股份增加了 43,573.5%。GAMMA Investing LLC 現在擁有 3,661,589 股該醫療研究公司的股票，價值 1,140,768,000 美元，此前在上個季度又購買了 3,653,205 股。Capital International Investors 在第四季度將其在安進的股份增加了 40.1%。Capital International Investors 現在擁有 12,212,065 股該醫療研究公司的股票，價值 3,182,843,000 美元，此前在上個季度又購買了 3,495,503 股。最後，查爾斯·施瓦布投資管理公司在第四季度將其在安進的股份增加了 25.4%。查爾斯·施瓦布投資管理公司現在擁有 13,205,604 股該醫療研究公司的股票，價值 3,441,909,000 美元，此前在上個季度又購買了 2,672,975 股。目前 76.50% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Amgen Stock Performance</h2>
<div class="lb-trans"><h2>安進股票表現</h2>
</div><p>NASDAQ:AMGN opened at $287.01 on Thursday. The firm has a market capitalization of $154.33 billion, a PE ratio of 38.01, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The business's fifty day moving average price is $282.39 and its 200 day moving average price is $285.31. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.</p>
<div class="lb-trans"><p>NASDAQ:AMGN 週四開盤價為 287.01 美元。該公司的市值為 1543.3 億美元，市盈率為 38.01，市盈增長比率為 2.63，貝塔值為 0.51。該公司的 50 日移動平均價格為 282.39 美元，200 日移動平均價格為 285.31 美元。安進的債務與股本比率為 9.62，流動比率為 1.26，速動比率為 0.95。安進公司的 12 個月最低價為 253.30 美元，12 個月最高價為 346.85 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 12/2 - 12/6</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 12/2 - 12/6</li>
</ul>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Amgen's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.96 earnings per share. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>安進（NASDAQ:AMGN - 獲取免費報告）最近一次發佈財報是在 5 月 1 日，醫療研究公司報告該季度每股收益為 4.90 美元，超出市場共識預期的 4.18 美元，超出 0.72 美元。該季度的收入為 81.5 億美元，而分析師預期為 80.5 億美元。安進的股本回報率為 176.32%，淨利潤率為 12.24%。安進該季度的收入較去年同期增長了 9.4%。在去年同期，該公司每股收益為 3.96 美元。平均而言，賣方分析師預計安進公司在當前財年將發佈每股收益 20.62 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several research analysts have recently weighed in on the company. Guggenheim assumed coverage on Amgen in a report on Tuesday, May 20th. They set a &#34;neutral&#34; rating and a $288.00 target price on the stock. Wells Fargo &amp; Company restated an &#34;equal weight&#34; rating on shares of Amgen in a report on Wednesday, February 5th. Erste Group Bank cut Amgen from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, May 8th. Citigroup restated a &#34;neutral&#34; rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Bank of America upped their price objective on Amgen from $275.00 to $294.00 and gave the company an &#34;underperform&#34; rating in a report on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of &#34;Hold&#34; and a consensus price target of $309.22.</p>
<div class="lb-trans"><p>幾位研究分析師最近對該公司進行了評估。Guggenheim 在 5 月 20 日的報告中開始覆蓋安進，給予 “中性” 評級和 288.00 美元的目標價。富國銀行在 2 月 5 日的報告中重申了對安進股票的 “持平” 評級。Erste Group Bank 在 5 月 8 日的報告中將安進的評級從 “強力買入” 下調至 “持有”。花旗集團在 2 月 5 日的報告中重申了對安進股票的 “中性” 評級。最後，美國銀行在 3 月 5 日的報告中將安進的目標價從 275.00 美元上調至 294.00 美元，並給予該公司 “表現不佳” 的評級。兩位股票研究分析師給予該股票 “賣出” 評級，十二位給予 “持有” 評級，九位給予 “買入” 評級，二位給予 “強力買入” 評級。根據 MarketBeat 的數據，安進目前的平均評級為 “持有”，共識目標價為 309.22 美元。</p>
</div><ul>
<li>Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?</li>
</ul>
<div class="lb-trans"><ul>
<li>安進股票因減肥藥數據下跌：過度反應還是合理？</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on Amgen</strong></p>
<div class="lb-trans"><p><strong>查看我們對安進的最新分析</strong></p>
</div><h2>Amgen Profile</h2>
<div class="lb-trans"><h2>安進簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>安進公司在全球範圍內發現、開發、生產和交付人類治療藥物。該公司的主要產品包括用於治療斑塊型銀屑病、類風濕性關節炎和銀屑病關節炎的恩利昔單抗；用於治療成人斑塊型銀屑病、銀屑病關節炎和與貝赫切特病相關的口腔潰瘍的 Otezla；用於治療絕經後女性骨質疏鬆症的 Prolia；用於預防骨骼相關事件的 XGEVA；可減少心肌梗死、中風和冠狀血管重建風險的 Repatha；用於治療免疫性血小板減少症患者的 Nplate；用於治療複發性或難治性多發性骨髓瘤患者的 KYPROLIS；用於治療紅細胞數量低於正常水平和貧血的 Aranesp；用於治療絕經後男性和女性骨質疏鬆症的 EVENITY；用於治療野生型 RAS 轉移性結直腸癌患者的 Vectibix；用於治療急性淋巴細胞白血病患者的 BLINCYTO；用於治療甲狀腺眼病的 TEPEZZA；以及用於治療慢性難治性痛風的 KRYSTEXXA。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Canadian Penny Stocks: Can They Make You Rich?</li>
<li>Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause?</li>
<li>Election Stocks: How Elections Affect the Stock Market</li>
<li>Top Dividend Plays With Strong Analyst Ratings</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Robinhood Stock Keeps Giving Investors Reasons To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過安進</li>
<li>加拿大便士股票：它們能讓你致富嗎？</li>
<li>Intuit 的人工智能熱潮：股票飆升，但投資者應該暫停嗎？</li>
<li>選舉股票：選舉如何影響股市</li>
<li>強分析師評級的頂級分紅股票</li>
<li>ETF 支付分紅嗎？你需要知道的</li>
<li>Robinhood 股票持續給投資者買入理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒是由敍事科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在安進嗎？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮安進之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而安進並不在名單上。</p>
</div><p>While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然安進目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Channel Wealth LLC 削減了其在安進公司（NASDAQ:AMGN）的股票頭寸